ArticleDrug design, development and therapy2025

SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy.

Xianglin Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.